Title : Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.

Pub. Date : 2021 Jul 12

PMID : 34143979






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The combination of PD-L1 inhibitor durvalumab and PARP inhibitor olaparib added to standard paclitaxel neoadjuvant chemotherapy (durvalumab/olaparib/paclitaxel (DOP)) was investigated in the phase II I-SPY2 trial of stage II/III HER2-negative breast cancer. olaparib collagen type XI alpha 2 chain Homo sapiens